{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:42:20Z","timestamp":1788316940477,"version":"build-2803163510"},"reference-count":67,"publisher":"Informa UK Limited","issue":"12","license":[{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2025,12,2]]},"DOI":"10.1080\/14712598.2025.2608209","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T08:38:50Z","timestamp":1766479130000},"page":"1299-1312","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":6,"title":["Current status and future potential of CD123-based targeted therapies for acute leukemia"],"prefix":"10.1080","volume":"25","author":[{"given":"Shukaib","family":"Arslan","sequence":"first","affiliation":[{"name":"City of Hope National Medical Center","place":["Duarte, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Aribi","sequence":"additional","affiliation":[{"name":"City of Hope National Medical Center","place":["Duarte, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Stein","sequence":"additional","affiliation":[{"name":"City of Hope National Medical Center","place":["Duarte, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Aldoss","sequence":"additional","affiliation":[{"name":"City of Hope National Medical Center","place":["Duarte, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"issue":"12","key":"e_1_3_5_3_1","first-page":"1261","article-title":"Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies","volume":"86","author":"Munoz L","year":"2001","unstructured":"Munoz L, Nomdedeu JF, Lopez O, et al. Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies. Haematologica. 2001;86(12):1261\u20131269.","journal-title":"Haematologica"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14146"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401903"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-03-0852"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.047894"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01595"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.98561"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-205837"},{"issue":"15","key":"e_1_3_5_11_1","first-page":"2034","article-title":"Expression of CD123 and CD114 on the bone marrow cells of patients with myelodysplastic syndrome","volume":"123","author":"Yue LZ","year":"2010","unstructured":"Yue LZ, Fu R, Wang HQ, et al. Expression of CD123 and CD114 on the bone marrow cells of patients with myelodysplastic syndrome. Chin Med J (Engl). 2010;123(15):2034\u20132037.","journal-title":"Chin Med J (Engl)"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2014.10.013"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI87366"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.205252"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404349"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-015-3272-y"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.348"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.52"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0645-z"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0773-5"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/protein\/13.8.575"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.7006"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1815105"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701799035"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011721"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018017517"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00674-5"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-128648"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS7073"},{"key":"e_1_3_5_30_1","unstructured":"Phase 1 study of FLAG-Ida with pivekimab sunirine (PVEK [IMGN632]) for adults with newly diagnosed adverse-risk acute myeloid leukemia and other high-grade myeloid neoplasms [Internet]. 2023. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06034470"},{"key":"e_1_3_5_31_1","unstructured":"A phase 1b\/2 study of IMGN632 as monotherapy or combination with venetoclax and\/or azacitidine for participants with CD123-positive acute myeloid leukemia [Internet]. 2019. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04086264"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-17-0742"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.330.330"},{"key":"e_1_3_5_34_1","unstructured":"A phase 1 study of SGN-CD123A in patients with relapsed or refractory acute myeloid leukemia (AML) [Internet]. 2016. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02848248"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-187642"},{"key":"e_1_3_5_36_1","unstructured":"A modular phase I\/II open-label multicenter study to assess the safety tolerability pharmacokinetics and preliminary antitumor activity of AZD9829 as monotherapy or in combination in patients with CD123-positive hematological malignancies [Internet]. 2023. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06179511"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2010.04.001"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa5693"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-575704"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007732"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-208170"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2024.2343029"},{"key":"e_1_3_5_43_1","unstructured":"A phase 1 first-in-human dose escalation study of MGD024 a CD123 x CD3 bispecific DART molecule in patients with select relapsed or refractory hematologic malignancies [Internet]. 2022. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05362773"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010956"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-208684"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-119786"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13164113"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.2824.2824"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13467"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000968884.66387.cd"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709919"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61403-3"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-09-529537"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0159477"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12282"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-12-474056"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6074.TUMIMM18-PR14"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-169928"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009759"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-177867"},{"key":"e_1_3_5_63_1","unstructured":"Clinicaltrials.gov. CD123-directed T-Cell therapy for acute myelogenous leukemia (CATCHAML). 2025."},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-170201"},{"key":"e_1_3_5_65_1","unstructured":"Multicenter open-label phase 1 study of Allo-RevCAR01-T-CD123 consisting of genetically modified T cells carrying reverse chimeric antigen receptors (Allo RevCAR01 t) in combination with CD123 target module (R-TM123) for the treatment of patients with selected hematologic malignancies positive for CD123 [Internet]. 2023. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05949125"},{"key":"e_1_3_5_66_1","unstructured":"Phase 1 study of lentivirally transduced T cells engineered to contain anti-CD123 linked to TCR\u03b6 and 4-1BB signaling domains in subjects with refractory or relapsed acute myeloid leukemia [Internet]. 2018. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03766126"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03271-5"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-118526"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2024.2420614"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2025.2608209","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T03:11:17Z","timestamp":1767150677000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2025.2608209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,2]]},"references-count":67,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12,2]]}},"alternative-id":["10.1080\/14712598.2025.2608209"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2025.2608209","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-06-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}